Citation: Yiyao Wan, Wen Chen, Yan Yu, Meng Pan, Kun Shi, Zhiyong Qian. Biomaterial-based drug delivery systems for the therapy of malignant pleural effusion[J]. Chinese Chemical Letters, ;2026, 37(1): 111513. doi: 10.1016/j.cclet.2025.111513 shu

Biomaterial-based drug delivery systems for the therapy of malignant pleural effusion

Yiyao Wan ^{a, c, d, 1} ,
Wen Chen ^{a, 1} ,
Yan Yu ^b ,
Meng Pan ^a ,
Kun Shi ^{a, *,} ,
Zhiyong Qian ^{a, *,}

a.
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China
b.
Department of Chemistry, Xihua University, Chengdu 610039, China
c.
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Chengdu 610041, China
d.
Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China

nicolekun@163.com

zhiyongqian@scu.edu.cn

Received Date: 7 March 2025
Revised Date: 24 June 2025
Accepted Date: 25 June 2025
Available Online: 27 June 2025

Figures(8)

Malignant pleural effusion (MPE) is a serious disease caused by malignant tumors with high morbidity and mortality. Chemotherapy, immunotherapy, and antiangiogenic therapy are common treatments for MPE at present. However, traditional chemotherapeutic drugs have many side effects and can easily lead to drug resistance in patients. The complex tumor microenvironment (TME) of MPE directly reduces the antitumor efficacy of immunotherapy. Fortunately, drug delivery systems (DDSs) based on biomaterials have the ability to overcome some of the drawbacks of conventional treatments by improving drug stability, increasing the accuracy of tumor cell targeting, reducing toxic side effects, and remodeling TME, ultimately improving drug efficacy. Therefore, the purpose of this review is to provide an overview and discussion of the latest progress in biomaterial-based DDSs for the treatment of MPE. We discuss the application of biomaterials in the treatment of MPE from multiple perspectives, including chemotherapy, immunotherapy, combination therapy, and pleurodesis, where microspheres, cell membrane-derived microparticles (MPs), micelles, nanoparticles, and liposomes, are involved. The application of these biomaterials has been proven to have great potential in the treatment of MPE, providing a new idea for follow-up research.
- Malignant pleural effusion,
- Drug delivery systems,
- Chemotherapy,
- Immunotherapy,
- Combination therapy,
- Pleurodesis
1. [1]
  K. Skok, G. Hladnik, A. Grm, A. Crnjac, Medicina 55 (2019) 490. doi: 10.3390/medicina55080490
2. [2]
  A.G. Villanueva, Management of malignant pleural effusions. In: A. Ernst, F. Herth (eds), Principles and Practice of Interventional Pulmonology. Springer, New York, 2013, pp. 665–674.
3. [3]
  E. Penz, K.N. Watt, C.A. Hergott, et al., Cancer Manag. Res. 9 (2017) 229–241. doi: 10.2147/CMAR.S95663
4. [4]
  Z. Chen, C.M. Fillmore, P.S. Hammerman, et al., Nat. Rev. Cancer 14 (2014) 535–546. doi: 10.1038/nrc3775
5. [5]
  J.M. Porcel, A. Gasol, S. Bielsa, et al., Respirology 20 (2015) 654–659. doi: 10.1111/resp.12496
6. [6]
  M.E. Roberts, E. Neville, R.G. Berrisford, et al., Thorax 65 (2010) ii32-ii40.
7. [7]
  A.C. Bibby, P. Dorn, I. Psallidas, et al., Eur. Respir. J. 52 (2018) 1800349. doi: 10.1183/13993003.00349-2018
8. [8]
  Y. Chen, N.W. Mathy, H. Lu, Mol. Med. Rep. 17 (2018) 8019–8030.
9. [9]
  M.M. Zamboni, C.T. da Silva, Jr., R. Baretta, et al., BMC Pulm. Med. 15 (2015) 29. doi: 10.1186/s12890-015-0025-z
10. [10]
  R. Asciak, N.M. Rahman, Clin. Chest Med. 39 (2018) 181–193. doi: 10.1016/j.ccm.2017.11.004
11. [11]
  Chinese Thoracic Society, Chinese Medical Association, Chin. J. Tuberculosis Respirat. Dis. 46 (2023) 1189–1203.
12. [12]
  F. Gonnelli, W. Hassan, M. Bonifazi, et al., Respir. Res. 25 (2024) 47. doi: 10.1186/s12931-024-02684-7
13. [13]
  G.T. Stathopoulos, I. Kalomenidis, Curr. Opin. Pulm. Med. 15 (2009) 343–352. doi: 10.1097/MCP.0b013e32832af07c
14. [14]
  F. Economidou, G. Margaritopoulos, K.M. Antoniou, N.M. Siafakas, Exp. Ther. Med. 1 (2010) 3–7. doi: 10.3892/etm_00000001
15. [15]
  S. Wen, K. Zhang, Y. Li, et al., Chin. Chem. Lett. 31 (2020) 3153–3157. doi: 10.1016/j.cclet.2020.03.077
16. [16]
  D.O. Bates, Cardiovasc. Res. 87 (2010) 262–271. doi: 10.1093/cvr/cvq105
17. [17]
  D. Marquez-Medina, S. Popat, Clin. Transl. Oncol. 18 (2016) 760–768. doi: 10.1007/s12094-015-1464-y
18. [18]
  Y. Sun, Y. Hu, C. Wan, et al., Biomater. Sci. 9 (2021) 6381–6390. doi: 10.1039/d1bm00971k
19. [19]
  Z. Xiang, X. Deng, W. He, et al., Ann. Med. 54 (2022) 1357–1371. doi: 10.1080/07853890.2022.2071977
20. [20]
  C.G. Willett, Y. Boucher, E. di Tomaso, et al., Nat. Med. 10 (2004) 145–147. doi: 10.1038/nm988
21. [21]
  D. Zhao, H. Hou, X. Zhang, OncoTargets Ther. 11 (2018) 4137–4147. doi: 10.2147/ott.s172305
22. [22]
  Q. Du, J. Zou, Z. Huang, et al., Chin. Chem. Lett. 34 (2023) 107763. doi: 10.1016/j.cclet.2022.107763
23. [23]
  G.T. Stathopoulos, I. Kalomenidis, Am. J. Respir. Crit. Care Med. 186 (2012) 487–492. doi: 10.1164/rccm.201203-0465PP
24. [24]
  H.H. Yeh, W.W. Lai, H.H. Chen, et al., Oncogene 25 (2006) 4300–4309. doi: 10.1038/sj.onc.1209464
25. [25]
  A. Marazioti, C.A. Kairi, M. Spella, et al., PLoS One 8 (2013) e71207. doi: 10.1371/journal.pone.0071207
26. [26]
  G.T. Stathopoulos, T.P. Sherrill, S.P. Karabela, et al., Am. J. Respir. Crit. Care Med. 182 (2010) 1273–1281. doi: 10.1164/rccm.201001-0001OC
27. [27]
  Y.C. Gary Lee, D. Melkerneker, P.J. Thompson, et al., Am. J. Respir. Crit. Care Med. 165 (2002) 88–94. doi: 10.1164/ajrccm.165.1.2104006
28. [28]
  E. Fernandes, J.A. Ferreira, P. Andreia, et al., J. Control. Release 209 (2015) 288–307. doi: 10.1016/j.jconrel.2015.05.003
29. [29]
  Y. Fan, A. Chen, J. Zhu, et al., Cancer Lett. 588 (2024) 216777. doi: 10.1016/j.canlet.2024.216777
30. [30]
  S. Taefehshokr, A. Parhizkar, S. Hayati, et al., Pathol. Res. Pract. 229 (2022) 153723. doi: 10.1016/j.prp.2021.153723
31. [31]
  B. Shen, M. Tan, Z. Wang, et al., J. Oncol. 2022 (2022) 1476038.
32. [32]
  L. Gandhi, D. Rodríguez-Abreu, S. Gadgeel, et al., N. Engl. J. Med. 378 (2018) 2078–2092. doi: 10.1056/nejmoa1801005
33. [33]
  R. Joshi, A. Gupta, C.D. Kaur, Application of biomaterials in cancer research. In: Malviya, R., Sundram, S. (eds), Targeted Cancer Therapy in Biomedical Engineering, Springer Nature Singapore, Singapore, 2023, pp. 245–289.
34. [34]
  K. Krukiewicz, J.K. Zak, Mater. Sci. Eng. C Mater. Biol. Appl. 62 (2016) 927–942. doi: 10.1016/j.msec.2016.01.063
35. [35]
  W. Chen, K. Shi, Y. Yu, et al., Chin. Chem. Lett. 35 (2024) 109159. doi: 10.1016/j.cclet.2023.109159
36. [36]
  Y. Li, J. Cui, C. Li, et al., Chin. Chem. Lett. 34 (2023) 108180. doi: 10.1016/j.cclet.2023.108180
37. [37]
  D. Katiyar, Mater. Today Proc (2023), doi:10.1016/j.matpr.2023.05.460. doi: 10.1016/j.matpr.2023.05.460
38. [38]
  Y. Chao, L. Xu, C. Liang, et al., Nat. Biomed. Eng. 2 (2018) 611–621. doi: 10.1038/s41551-018-0262-6
39. [39]
  .P. Torchilin, Eur. J. Pharm. Sci. 11 (2000) S81–S91. doi: 10.1016/S0928-0987(00)00166-4
40. [40]
  Y.B. Meng, J. Wu, Chin. J. Polym. Sci. 40 (2022) 1016–1027. doi: 10.1007/s10118-022-2701-9
41. [41]
  J. Xie, Y. Lu, B. Yu, et al., Chin. Chem. Lett. 31 (2020) 1173–1177. doi: 10.1016/j.cclet.2019.10.030
42. [42]
  J. Huang, X. You, P. Xin, et al., Chin. Chem. Lett. 32 (2021) 1737–1742. doi: 10.1016/j.cclet.2020.12.006
43. [43]
  X. You, L. Wang, J. Zhang, et al., Chin. Chem. Lett. 34 (2023) 107720. doi: 10.1016/j.cclet.2022.07.063
44. [44]
  X. Wu, X. Chen, X. Wang, et al., Chin. Chem. Lett. 35 (2024) 108756. doi: 10.1016/j.cclet.2023.108756
45. [45]
  Y. Wang, C. Zhang, S. Han, et al., Chin. Chem. Lett. 35 (2024) 109578. doi: 10.1016/j.cclet.2024.109578
46. [46]
  J. Herrstedt, P. Clementsen, O.P. Hansen, Eur. J. Cancer 28a (1992) 1070–1073.
47. [47]
  H. Zhou, W. Wu, X. Tang, et al., Medicine 96 (2017) e5532. doi: 10.1097/MD.0000000000005532
48. [48]
  Y. Zhang, T. Li, Y. Hu, et al., Chin. Chem. Lett. 33 (2022) 2507–2511. doi: 10.1016/j.cclet.2021.11.076
49. [49]
  S. Rivankar, J. Cancer Res. Ther. 10 (2014) 853–858. doi: 10.4103/0973-1482.139267
50. [50]
  O. Ike, Y. Shimizu, S. Hitomi, et al., Chest 99 (1991) 911–915. doi: 10.1378/chest.99.4.911
51. [51]
  O. Ike, Y. Shimizu, Y. Ikada, et al., Biomaterials 12 (1991) 757–762. doi: 10.1016/0142-9612(91)90026-7
52. [52]
  Y. Tan, A. Tajik, J. Chen, et al., Nat. Commun. 5 (2014) 4619. doi: 10.1038/ncomms5619
53. [53]
  Z.H. Wu, C.L. Ji, H. Li, et al., Eur. Rev. Med. Pharmacol. Sci. 17 (2013) 2420–2427.
54. [54]
  H. Zhang, K. Tang, Y. Zhang, et al., Cancer Immunol. Res. 3 (2015) 196–205. doi: 10.1158/2326-6066.CIR-14-0177
55. [55]
  K. Tang, Y. Zhang, H. Zhang, et al., Nat. Commun. 3 (2012) 1282. doi: 10.1038/ncomms2282
56. [56]
  J. Ma, Y. Zhang, K. Tang, et al., Cell Res. 26 (2016) 713–727. doi: 10.1038/cr.2016.53
57. [57]
  M. Pourmadadi, A. Ghaemi, M. Shaghaghi, et al., J. Drug Deliv. Sci. Technol. 82 (2023) 104338. doi: 10.1016/j.jddst.2023.104338
58. [58]
  T. Liu, H. Zou, J. Mu, et al., Chin. Chem. Lett. 32 (2021) 1751–1754. doi: 10.1016/j.cclet.2020.12.008
59. [59]
  B. Sun, H. Jing, M.T. Mabrouk, et al., Pharm. Dev. Technol. 25 (2020) 1281–1288. doi: 10.1080/10837450.2020.1818780
60. [60]
  Z.H. Siddik, Oncogene 22 (2003) 7265–7279. doi: 10.1038/sj.onc.1206933
61. [61]
  K. Hotta, K. Matsuo, H. Ueoka, et al., J. Clin. Oncol. 22 (2004) 3852–3859. doi: 10.1200/JCO.2004.02.109
62. [62]
  Y.K. Chao, Y.W. Wen, K.S. Liu, et al., Int. J. Pharm. 484 (2015) 38–43. doi: 10.1016/j.ijpharm.2015.02.048
63. [63]
  X. Bai, F. Cerimele, M. Ushio-Fukai, et al., J. Biol. Chem. 278 (2003) 35501–35507. doi: 10.1074/jbc.M302967200
64. [64]
  F. Fang, C. Gong, Z. Qian, et al., ACS Nano 3 (2009) 4080–4088. doi: 10.1021/nn900785b
65. [65]
  P. Murthy, C.N. Ekeke, K.L. Russell, et al., Oncoimmunology 8 (2019) e1554969. doi: 10.1080/2162402x.2018.1554969
66. [66]
  T.L. Whiteside, S. Demaria, M.E. Rodriguez-Ruiz, et al., Clin. Cancer Res. 22 (2016) 1845–1855. doi: 10.1158/1078-0432.CCR-16-0049
67. [67]
  T.F. Gajewski, L. Corrales, J. Williams, et al., Adv. Exp. Med. Biol. 1036 (2017) 19–31. doi: 10.1007/978-3-319-67577-0_2
68. [68]
  X. Li, J. He, W. He, Acta Pharm. Sin. B 14 (2024) 5515–5517. doi: 10.1016/j.apsb.2024.08.011
69. [69]
  Y. Xie, X. Li, J. Wu, et al., Chin. Chem. Lett. 34 (2023) 108202. doi: 10.1016/j.cclet.2023.108202
70. [70]
  A. Khurana, S. Tekula, M.A. Saifi, et al., Biomed. Pharmacother. 111 (2019) 802–812. doi: 10.1016/j.biopha.2018.12.146
71. [71]
  Y. Huang, Y. Fu, M. Li, et al., Angew. Chem. Int. Ed. 59 (2020) 4406–4414. doi: 10.1002/anie.201910615
72. [72]
  Y. Zhang, M. Zhang, Y. Jiang, et al., J. Cancer Res. Clin. Oncol. 144 (2018) 2177–2186. doi: 10.1007/s00432-018-2718-1
73. [73]
  Z. Song, W. Luo, H. Zheng, et al., Adv. Healthc. Mater. 10 (2021) e2100149. doi: 10.1002/adhm.202100149
74. [74]
  L. Chiossone, P.Y. Dumas, M. Vienne, E. Vivier, Nat. Rev. Immunol. 18 (2018) 671–688. doi: 10.1038/s41577-018-0061-z
75. [75]
  H. Zuo, P.M. Ueland, Ø. Midttun, et al., Ann. Oncol. 30 (2019) 478–485. doi: 10.1093/annonc/mdz002
76. [76]
  S. Liu, N. Li, H. Lai, et al., Adv. Funct. Mater. 34 (2024) 2401264. doi: 10.1002/adfm.202401264
77. [77]
  D. Meng, H. Pan, W. He, et al., Adv. Funct. Mater. 32 (2022) 2202603. doi: 10.1002/adfm.202202603
78. [78]
  C. Li, Y. Zhang, Y. Wan, et al., Chin. Chem. Lett. 32 (2021) 1615–1625. doi: 10.1016/j.cclet.2021.01.001
79. [79]
  L. Sun, J. Wu, F. Du, et al., Science 339 (2013) 786–791. doi: 10.1126/science.1232458
80. [80]
  Y. Liu, L. Wang, Q. Song, et al., Nat. Nanotechnol. 17 (2022) 206–216. doi: 10.1038/s41565-021-01032-w
81. [81]
  F.G. Herrera, J. Bourhis, G. Coukos, CA Cancer J. Clin. 67 (2017) 65–85.
82. [82]
  C. Mothersill, C.B. Seymour, Nat. Rev. Cancer 4 (2004) 158–164. doi: 10.1038/nrc1277
83. [83]
  C. Wan, Y. Sun, Y. Tian, et al., Sci. Adv. 6 (2020) eaay9789. doi: 10.1126/sciadv.aay9789
84. [84]
  J.L. Liang, G.F. Luo, W.H. Chen, X.Z. Zhang, Adv. Mater. 33 (2021) e2007630. doi: 10.1002/adma.202007630
85. [85]
  W. Mu, Q. Chu, Y. Liu, N. Zhang, Nanomicro Lett. 12 (2020) 142.
86. [86]
  M.S. Feng, P. Guo, L.X. Jiang, et al., Chin. Chem. Lett. 20 (2009) 178–180. doi: 10.1016/j.cclet.2008.10.027
87. [87]
  C.S. Wu, C.H. Wang, J.L. Zhang, et al., Chin. Chem. Lett. 25 (2014) 447–450. doi: 10.1186/1556-276X-9-447
88. [88]
  M. Guo, F. Wu, G. Hu, et al., Sci. Transl. Med. 11 (2019) eaat5690. doi: 10.1126/scitranslmed.aat5690
89. [89]
  A.D. Gregory, A.M. Houghton, Cancer Res. 71 (2011) 2411–2416.
90. [90]
  P. Xu, K. Tang, J. Ma, et al., Cancer Immunol. Res. 8 (2020) 1193–1205. doi: 10.1158/2326-6066.cir-19-0789
91. [91]
  X. Dong, Y. Huang, T. Yi, et al., Front. Immunol. 13 (2022) 1002938. doi: 10.3389/fimmu.2022.1002938
92. [92]
  J. Sunshine, J.M. Taube, Curr. Opin. Pharmacol. 23 (2015) 32–38. doi: 10.1016/j.coph.2015.05.011
93. [93]
  L.H. Yan, X.L. Liu, S.S. Mo, et al., Am. J. Transl. Res. 13 (2021) 923–934.
94. [94]
  W. Chen, W. Zeng, J. Sun, et al., ACS Nano 9 (2015) 6069–6076. doi: 10.1021/acsnano.5b01203
95. [95]
  J.S. He, S.J. Liu, Y.R. Zhang, et al., Front. Pharmacol. 12 (2021) 687399. doi: 10.3389/fphar.2021.687399
96. [96]
  W. Chen, F. Guo, Z. Ren, et al., Front. Bioeng. Biotechnol. 10 (2022) 973892. doi: 10.3389/fbioe.2022.973892
97. [97]
  Z. Kang, S. Li, Y. Li, et al., Chin. Chem. Lett. 36 (2024) 110447.
98. [98]
  S. Parakh, M. Ernst, A.R. Poh, Cancers (Basel) 13 (2021) 6228. doi: 10.3390/cancers13246228
99. [99]
  E. Albesiano, M. Davis, A.P. See, et al., Cancer Res. 70 (2010) 6467–6476. doi: 10.1158/0008-5472.CAN-09-4058
100. [100]
  X. Fu, Y. Shi, Z. Gu, et al., Asian J. Pharm. Sci. 19 (2024) 100925.
101. [101]
  F. Rodriguez-Panadero, A. Montes-Worboys, Respiration 83 (2012) 91–98. doi: 10.1159/000335419
102. [102]
  M. Mierzejewski, P. Korczynski, R. Krenke, J.P. Janssen, Respir. Res. 20 (2019) 247. doi: 10.1186/s12931-019-1204-x
103. [103]
  V.B. Antony, N. Nasreen, K.A. Mohammed, et al., Chest 126 (2004) 1522–1528. doi: 10.1378/chest.126.5.1522
104. [104]
  A. Dipper, H.E. Jones, R. Bhatnagar, et al., Cochrane Database Syst. Rev. 4 (2020) Cd010529.
105. [105]
  J. Baxter, T.A. Lima, R. Huneke, et al., J. Cardiothorac. Surg. 15 (2020) 58. doi: 10.1186/s13019-020-01098-y
106. [106]
  T.N. Beck, A.Y. Deneka, L. Chai, et al., BMC Cancer 19 (2019) 614. doi: 10.1186/s12885-019-5777-z
107. [107]
  T.A. Lima, R.A. Coler, G.W. Laub, et al., Drug Deliv. 28 (2021) 733–740. doi: 10.1080/10717544.2021.1895910
108. [108]
  S. Antimisiaris, S. Mourtas, K. Papadia, Int. J. Pharm. 525 (2017) 293–312. doi: 10.1016/j.ijpharm.2017.01.056
109. [109]
  K. Thapa Magar, G.F. Boafo, X. Li, et al., Chin. Chem. Lett. 33 (2022) 587–596. doi: 10.1016/j.cclet.2021.08.020
110. [110]
  A. Marazioti, K. Papadia, A. Giannou, et al., Int. J. Nanomedicine 14 (2019) 3773–3784. doi: 10.2147/ijn.s202568
111. [111]
  A.H. Matloob, S. Mourtas, P. Klepetsanis, S.G. Antimisiaris, Int. J. Pharm. 476 (2014) 108–115. doi: 10.1016/j.ijpharm.2014.09.041
112. [112]
  J. Lal, S.K. Gupta, D. Thavaselvam, D.D. Agarwal, Chin. Chem. Lett. 27 (2016) 1067–1072. doi: 10.1016/j.cclet.2016.03.032
113. [113]
  M.K. Shanmugam, G. Rane, M.M. Kanchi, et al., Molecules 20 (2015) 2728–2769. doi: 10.3390/molecules20022728
114. [114]
  R. Greil, S. Greil-Ressler, L. Weiss, et al., Cancer Chemother. Pharmacol. 82 (2018) 695–706. doi: 10.1007/s00280-018-3654-0
115. [115]
  A. Hocking, S. Tommasi, P. Sordillo, S. Klebe, Int. J. Nanomedicine 15 (2020) 943–952. doi: 10.2147/ijn.s237536
116. [116]
  A.J. Hocking, A.L. Farrall, S. Newhouse, et al., BMJ Open 11 (2021) e047075. doi: 10.1136/bmjopen-2020-047075
117. [117]
  X. Li, Y. Lai, G. Wan, et al., Chin. J. Nat. Med. 22 (2024) 1100–1116.
1. [1]
  Ningyue Xu , Jun Wang , Lei Liu , Changyang Gong . Injectable hydrogel-based drug delivery systems for enhancing the efficacy of radiation therapy: A review of recent advances. Chinese Chemical Letters, 2024, 35(8): 109225-. doi: 10.1016/j.cclet.2023.109225
2. [2]
  Tingting Hu , Chao Shen , Xueyan Wang , Fengbo Wu , Zhiyao He . Tumor microenvironment-sensitive polymeric nanoparticles for synergetic chemo-photo therapy. Chinese Chemical Letters, 2024, 35(11): 109562-. doi: 10.1016/j.cclet.2024.109562
3. [3]
  Cheng-Zhe Gao , Hao-Ran Jia , Tian-Yu Wang , Xiao-Yu Zhu , Xiaofeng Han , Fu-Gen Wu . A dual drug-loaded tumor vasculature-targeting liposome for tumor vasculature disruption and hypoxia-enhanced chemotherapy. Chinese Chemical Letters, 2025, 36(1): 109840-. doi: 10.1016/j.cclet.2024.109840
4. [4]
  Wenbin Zhou , Yafei Gao , Xinyu Feng , Yanqing Zhang , Cong Yang , Lanxi He , Fenghe Zhang , Xiaoguang Li , Qing Li . Biomimetic nanoplatform integrates FRET-enhanced photodynamic therapy and chemotherapy for cascaded revitalization of the tumor immune microenvironment in OSCC. Chinese Chemical Letters, 2025, 36(1): 109763-. doi: 10.1016/j.cclet.2024.109763
5. [5]
  Liangliang Jia , Ye Hong , Xinyu He , Ying Zhou , Liujiao Ren , Hongjun Du , Bin Zhao , Bin Qin , Zhe Yang , Di Gao . Fighting hypoxia to improve photodynamic therapy-driven immunotherapy: Alleviating, exploiting and disregarding. Chinese Chemical Letters, 2025, 36(2): 109957-. doi: 10.1016/j.cclet.2024.109957
6. [6]
  Jiechen Liu , Xiaoguang Li , Ruiyang Xia , Yuqi Wang , Fenghe Zhang , Yongzhi Pang , Qing Li . Efficient suppression of oral squamous cell carcinoma through spatial dimension conversion drug delivery systems-enabled immunomodulatory-photodynamic therapy. Chinese Chemical Letters, 2024, 35(12): 109619-. doi: 10.1016/j.cclet.2024.109619
7. [7]
  Lijuan Liu , Zhihao Zhao , Feiwan Zou , Wukun Liu , Yunlong Lu . Advances in combination therapy for the treatment of estrogen receptor positive breast cancer. Chinese Chemical Letters, 2025, 36(10): 111451-. doi: 10.1016/j.cclet.2025.111451
8. [8]
  Yanyan Yin , Jun Guo , Shuo Zhang , Meng Xu , Yun Fu , Mengyi Zhang , Zhipeng Ma , Jiajia Ji , Siyuan Wu , Jinjie Zhang , Jianbo Li , Lei Wang . Research progress and prospect of tumor nanovaccine combination therapy strategy. Chinese Chemical Letters, 2025, 36(10): 110771-. doi: 10.1016/j.cclet.2024.110771
9. [9]
  Du Liu , Yuyan Li , Hankun Zhang , Benhua Wang , Chaoyi Yao , Minhuan Lan , Zhanhong Yang , Xiangzhi Song . Three-in-one erlotinib-modified NIR photosensitizer for fluorescence imaging and synergistic chemo-photodynamic therapy. Chinese Chemical Letters, 2025, 36(2): 109910-. doi: 10.1016/j.cclet.2024.109910
10. [10]
  Meng Sun , Jiazhen Yang , Leijiao Li , Yunhui Li , Wenliang Li , Jianxun Ding . Engineered bacteria potentiate cancer immunotherapy. Chinese Chemical Letters, 2025, 36(9): 111093-. doi: 10.1016/j.cclet.2025.111093
11. [11]
  Tianxu Zhang , Dexuan Xiao , Mi Zhou , Yunfeng Lin , Tao Zhang , Xiaoxiao Cai . Protective effect of osteogenic growth peptide functionalized tetrahedral DNA nanostructure on bone marrow and bone formation ability in chemotherapy-induced myelosuppressive mice. Chinese Chemical Letters, 2025, 36(8): 110594-. doi: 10.1016/j.cclet.2024.110594
12. [12]
  Weiqian Jin , Lin Liao , Tao Qin , Xiaoxuan Guan , Huyang Gao , Peng Liang , Ming Gao , Junyu Lu . Recent advances in nanomedicine therapy for bacterial pneumonia. Chinese Chemical Letters, 2025, 36(6): 110920-. doi: 10.1016/j.cclet.2025.110920
13. [13]
  Bohan Chen , Liming Gong , Jing Feng , Mingji Jin , Liqing Chen , Zhonggao Gao , Wei Huang . Research advances of nanoparticles for CAR-T therapy in solid tumors. Chinese Chemical Letters, 2024, 35(9): 109432-. doi: 10.1016/j.cclet.2023.109432
14. [14]
  Xiaofang Luo , Ye Wu , Xiaokun Zhang , Min Tang , Feiye Ju , Zuodong Qin , Gregory J Duns , Wei-Dong Zhang , Jiang-Jiang Qin , Xin Luan . Peptide-based strategies for overcoming multidrug-resistance in cancer therapy. Chinese Chemical Letters, 2025, 36(1): 109724-. doi: 10.1016/j.cclet.2024.109724
15. [15]
  Hao Sun , Shengke Li , Qian Liu , Minzan Zuo , Xueqi Tian , Kaiya Wang , Xiao-Yu Hu . Supramolecular prodrug vesicles for selective antimicrobial therapy employing a chemo-photodynamic strategy. Chinese Chemical Letters, 2025, 36(3): 109999-. doi: 10.1016/j.cclet.2024.109999
16. [16]
  Shuang Liang , Jianjun Yao , Dan Liu , Mengli Zhou , Yong Cui , Zhaohui Wang . Tumor-responsive covalent organic polymeric nanoparticles enhancing STING activation for cancer immunotherapy. Chinese Chemical Letters, 2025, 36(3): 109856-. doi: 10.1016/j.cclet.2024.109856
17. [17]
  Yuequan Wang , Congtian Wu , Chengcheng Feng , Qin Chen , Zhonggui He , Shenwu Zhang , Cong Luo , Jin Sun . Spatiotemporally-controlled supramolecular hybrid nanoassembly enabling ferroptosis-augmented photodynamic immunotherapy of cancer. Chinese Chemical Letters, 2025, 36(3): 109902-. doi: 10.1016/j.cclet.2024.109902
18. [18]
  Yanjun Cai , Yong Jiang , Yu Chen , Erzhuo Cheng , Yuan Gu , Yuwei Li , Qianqian Liu , Jian Zhang , Jifang Liu , Shisong Han , Bin Yang . Amplifying STING activation and immunogenic cell death by metal-polyphenol coordinated nanomedicines for enhanced cancer immunotherapy. Chinese Chemical Letters, 2025, 36(5): 110437-. doi: 10.1016/j.cclet.2024.110437
19. [19]
  Donghu Yu , Junneng Wang , Lei Hu , Youxian Wu , Tianqing Wang , Zhiyu Li , Zefen Wang , Qihang Ding , Yao Sun , Zhiqiang Li . Knowledge structures and research hotspots of immunotherapy for brain metastasis, glioma, meningioma, and pituitary adenoma: A bibliometric and visualization review. Chinese Chemical Letters, 2025, 36(12): 110995-. doi: 10.1016/j.cclet.2025.110995
20. [20]
  Chuyu Huang , Zhishan Liu , Linping Zhao , Zuxiao Chen , Rongrong Zheng , Xiaona Rao , Yuxuan Wei , Xin Chen , Shiying Li . Metal-coordinated oxidative stress amplifier to suppress tumor growth combined with M2 macrophage elimination. Chinese Chemical Letters, 2024, 35(12): 109696-. doi: 10.1016/j.cclet.2024.109696

Get Citation

PDF

XML

Metrics

PDF Downloads(0)
Abstract views(5)
HTML views(1)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142